MedTrace Logo

Cannabinoid Tablets for the Treatment of Pain From Osteoarthritis of the Knee

NCT04992962 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2021-08-06

No results posted yet for this study

Summary

The purpose of the study is to evaluate the efficacy of PG-OA-10CN and PG-OA-5TH tablets as a better pain reliever in patients with moderate to severe chronic pain due to osteoarthritis of the knee than a placebo.

Conditions

  • Osteoarthritis, Knee

Interventions

DRUG

CBD/CBN

A water-soluble sublingual tablet containing 10 mg of CBD and 10 mg of CBN.

DRUG

CBD/THC

A water-soluble sublingual tablet containing 10 mg of CBD and 5 mg of THC.

DRUG

Placebo

An inactive compound.

Sponsors & Collaborators

  • Pure Green

    lead INDUSTRY

Principal Investigators

  • Debra Kimless, M.D. · Pure Green Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-29
Primary Completion
2021-10-30
Completion
2021-11-14

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04992962 on ClinicalTrials.gov